Maiore Laura, Aragoni Maria Carla, Deiana Carlo, Cinellu Maria Agostina, Isaia Francesco, Lippolis Vito, Pintus Anna, Serratrice Maria, Arca Massimiliano
Dipartimento di Scienze Chimiche e Geologiche, Università degli Studi di Cagliari , S.S. 554 bivio per Sestu, 09042 Monserrato (Cagliari), Italy.
Inorg Chem. 2014 Apr 21;53(8):4068-80. doi: 10.1021/ic500022a. Epub 2014 Mar 28.
Gold(I) and gold(III) complexes derived from 2-(2'-pyridyl)benzimidazole (pbiH) were proven to be a promising class of in vitro antitumor agents against A2780 human ovarian cancer cells. In this paper, a comparative electrochemical, UV-vis absorption, and emission spectroscopic investigation is reported on pbiH, the two mononuclear Au(III) complexes [(pbi)AuX2] (X = Cl (1), AcO (2)), the four mononuclear Au(I) derivatives [(pbiH)AuCl] (3), [(pbiH)Au(PPh3)]PF6 ((4(+))(PF6(-))), [(pbi)Au(PPh3)] (5), and [(pbi)Au(TPA)] (6), the three mixed-valence Au(III)/Au(I) complexes [(μ-pbi)Au2Cl3] (7), [(Ph3P)Au(μ-pbi)AuX2]PF6 (X = Cl ((8(+))(PF6(-))), AcO ((9(+))(PF6(-)))), and the binuclear Au(I)-Au(I) compound [(μ-pbi)Au2(PPh3)2]PF6 ((10(+))(PF6(-))). All complexes feature irreversible reduction processes related to the Au(III)/Au(I) or Au(I)/Au(0) processes and peculiar luminescent emission at about 360-370 nm in CH2Cl2, with quantum yields that are remarkably lower ((0.7-14.5) × 10(-2)) in comparison to that determined for the free pbiH ligand (31.5 × 10(-2)) in the same solvent. The spectroscopic and electrochemical properties of all complexes were interpreted on the grounds of time-dependent PBE0/DFT calculations carried out both in the gas phase and in CH2Cl2 implicitly considered within the IEF-PCM SCRF approach. The electronic structure of the complexes, and in particular the energy and composition of the Kohn-Sham LUMOs, can be related to the antiproliferative properties against the A2780 ovarian carcinoma cell line, providing sound quantitative structure-activity relationships and shedding a light on the role played by the global charge and nature of ancillary ligands in the effectiveness of Au-based antitumor drugs.
源自2-(2'-吡啶基)苯并咪唑(pbiH)的金(I)和金(III)配合物被证明是一类有前景的体外抗人卵巢癌细胞A2780的抗肿瘤剂。本文报道了对pbiH、两种单核Au(III)配合物[(pbi)AuX2](X = Cl(1),AcO(2))、四种单核Au(I)衍生物(pbiH)AuCl、[(pbiH)Au(PPh3)]PF6((4(+))(PF6(-)))、(pbi)Au(PPh3)和(pbi)Au(TPA)、三种混合价Au(III)/Au(I)配合物(μ-pbi)Au2Cl3、[(Ph3P)Au(μ-pbi)AuX2]PF6(X = Cl((8(+))(PF6(-))),AcO((9(+))(PF6(-))))以及双核Au(I)-Au(I)化合物[(μ-pbi)Au2(PPh3)2]PF6((10(+))(PF6(-)))的电化学、紫外可见吸收和发射光谱的对比研究。所有配合物都具有与Au(III)/Au(I)或Au(I)/Au(0)过程相关的不可逆还原过程,并且在二氯甲烷中于约360 - 370 nm处有独特的发光发射,其量子产率与在相同溶剂中测定的游离pbiH配体(31.5×10(-2))相比显著更低((0.7 - 14.5)×10(-2))。所有配合物的光谱和电化学性质是基于在气相以及在IEF - PCM SCRF方法中隐式考虑的二氯甲烷中进行的含时PBE0/DFT计算来解释的。配合物的电子结构,特别是Kohn - Sham最低未占分子轨道的能量和组成,可与针对A2780卵巢癌细胞系的抗增殖性质相关联,提供合理的定量构效关系,并阐明辅助配体的整体电荷和性质在金基抗肿瘤药物有效性中所起的作用。